Soligenix, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited consolidated results. Soligenix is a development-stage biopharmaceutical company with Specialized BioTherapeutics and Public Health Solutions segments. Revenue is primarily from government grants and contracts, not product sales.
Key financial metrics
| Metric | Q1 2024 / March 31, 2024 | Prior comparable period / December 31, 2023 |
|---|---|---|
| Revenue | $117,029 | $257,178 in Q1 2023 |
| Gross profit (margin) | $0 (0%) | $31,138 (12%) in Q1 2023 |
| Operating expenses | $2.12 million | $2.18 million in Q1 2023 |
| Net loss | $1.92 million; $0.18 per share | $1.05 million; $0.36 per share in Q1 2023 |
| Cash used in operating activities | $1.34 million | $2.17 million in Q1 2023 |
| Cash and cash equivalents | $7.09 million | $8.45 million at December 31, 2023 |
| Working capital | $0.61 million | $3.36 million at December 31, 2023 |
| Convertible debt | $2.90 million principal; $3.00 million carrying value at fair value | $3.00 million principal before Q1 conversion |
| Total liabilities | $7.29 million | $7.27 million at December 31, 2023 |
Q1 2024 included $201,764 of total other income, including a $165,382 noncash gain from the change in fair value of convertible debt. The company reported $28,842 of net interest income in its statement of operations. Q1 2023 net loss was reduced by a $1.16 million income tax benefit from a state net operating loss carryforward sale; no comparable tax benefit was recorded in 2024.
Changes versus Q1 2023 and year-end
- Revenue fell 54%, and gross profit declined to zero, primarily because higher-margin SGX943 and CiVax grant funding concluded and HyBryte investigator-study revenue carried no margin.
- Research and development expense increased 16% to $1.10 million, mainly from preparation for the planned Behçet’s disease Phase 2a and confirmatory CTCL Phase 3 trials. General and administrative expense fell 17%, principally due to lower legal and professional fees than in Q1 2023.
- Net loss increased 83% year over year, primarily because Q1 2023 included the tax benefit. Cash declined 16% from year-end, while working capital fell 82%, reflecting operating cash use and reclassification of about $1 million of debt to current liabilities.
- Operating cash use was lower than in Q1 2023. The company reported a $1.35 million net decrease in cash for the quarter.
Outlook, liquidity, and material developments
- Going concern: Management stated that resources were expected to support operations and obligations through Q1 2025, but cash as of the filing date was not sufficient for at least 12 months after issuance of the financial statements. The filing says this raises substantial doubt about the company’s ability to continue as a going concern. Potential remedies—including financing, partnerships, grants, at-the-market stock sales, and debt amendments—were not committed.
- Subsequent offering: On April 22, 2024, Soligenix completed an offering of 3.275 million common shares, pre-funded warrants for 8.6 million shares, and common warrants for 11.875 million shares. It raised approximately $4.75 million gross and $4.3 million net for programs and working capital. The warrants may result in substantial dilution.
- Spending outlook: The company expects approximately $6.0 million of R&D expenditures over the next 12 months before contract and grant reimbursements, and approximately $0.3 million of expected reimbursements. Up to approximately $673,000 of active grant funding remained available at March 31, 2024, subject to agency terms.
- HyBryte: Following EMA agreement on key design components, the company targets enrollment in the confirmatory Phase 3 FLASH2 trial by the end of 2024, with top-line results anticipated in the second half of 2026. FDA feedback requires a second successful pivotal trial for an acceptable NDA and the FDA has expressed a preference for a longer comparative study; discussions continue.
- Other pipeline: SGX302 psoriasis development continues, with preliminary Cohort 2 results reported as clinically encouraging and well tolerated. SGX945 Behçet’s disease Phase 2a enrollment is expected in the second half of 2024. Further SGX942 oral mucositis development depends on designing a second Phase 3 trial and identifying a partner. Public Health Solutions programs rely substantially on government or other funding.
- Debt: Pontifax debt matures June 15, 2025 and is secured by substantially all company assets other than intellectual property. Scheduled principal payments as of March 31 were $2.25 million for the remainder of 2024 and $650,585 in 2025, assuming no further conversions. Pontifax converted $99,416 of principal into shares in January and a further $154,840 into shares on April 15.
- Nasdaq: The company had not met the $1.00 minimum bid-price requirement and was not eligible for a second standard compliance period because it did not meet the $5 million stockholders’ equity requirement. A March 26, 2024 hearing stayed trading suspension pending the panel’s written decision and any extension. The filing does not report the final decision.
- Other obligations and risks: Potential license and collaboration milestone payments total up to approximately $13.2 million, contingent on clinical or commercial success; a separate HyBryte FDA-approval milestone could require up to $5 million in restricted stock. Risks include clinical and regulatory uncertainty, financing needs, grant dependence, Nasdaq listing compliance, competition, and dilution. Management reported disclosure controls and procedures were effective as of March 31, 2024.
Most important facts for investors to verify
- Whether the April offering proceeds and any additional financing are sufficient to fund operations beyond the stated Q1 2025 horizon, given the going-concern warning.
- The Nasdaq Hearings Panel’s final decision, any extension terms, and the company’s ability to meet listing requirements.
- FLASH2 funding, enrollment timing, FDA development-path discussions, and whether a second pivotal trial can support a future NDA.
- Debt repayment or conversion terms and the resulting dilution from the April offering warrants, existing warrants, options, and convertible debt.
- Availability and continuation of government grants, contract reimbursements, and potential partners for pipeline programs.